Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR4 | P51679 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | PAX8 | Q06710 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | EDNRA | P25101 | 7/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | KMO | O15229 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6038953 | 0.89 | CCR4 (0.59) | CCR4ALDH1A1MEN1KMT2AMAOA | |
| SCHEMBL6038560 | 0.89 | CCR4 (0.58) | CCR4ALDH1A1NPC1RAB9APAX8 | |
| SCHEMBL6038535 | 0.88 | CCR4 (0.65) | CCR4NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL6038583 | 0.87 | CCR4 (0.60) | CCR4ALDH1A1NPC1RAB9APAX8 | |
| SCHEMBL6038707 | 0.85 | CCR4 (0.47) | CCR4ALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL6038637 | 0.83 | CCR4 (0.68) | CCR4SMN1; SMN2MEN1KMT2AEDNRA | |
| SCHEMBL6039115 | 0.81 | CCR4 (0.53) | CCR4 | |
| SCHEMBL6038499 | 0.80 | CCR4 (0.82) | CCR4EDNRA | |
| SCHEMBL6038792 | 0.76 | CCR4 (0.47) | CCR4ALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL6038976 | 0.75 | CCR4 (0.50) | CCR4ALDH1A1SMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060004010-A1 | Ccr4 antagonist and medical use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-05 | — | — | US | disclosed |
| EP-1541563-A1 | CCR4 ANTAGONIST AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004010-A1 | Ccr4 antagonist and medical use thereof | CCR4, CCR1, CCR9 | CCR4 1/4885ALDH1A1 2902/4885NPC1 1760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.